Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Trajan sees demand for life science products soften, hopeful for rebound next year

  • In News
  • May 9, 2024
  • Alinda Gupta
Trajan sees demand for life science products soften, hopeful for rebound next year

Melbourne-based developer and manufacturer of analytical and life sciences products Trajan Group (ASX: TRJ) expects its full-year revenue for FY24 to fall short of previous projections due to delays in order delivery and unexpected softening in the pharmaceutical sector. 

Trajan manufactures analytical and life sciences products and devices—including microscope slides, analytical syringes and micro-sampling tools for blood analysis. These products and solutions are used to analyse biological, food, and environmental samples.

Trajan’s net revenue for FY24 is likely to range between $154 million and $157 million, falling short of the low end of its previously stated guidance of $163 million. The Company attributes this discrepancy to slower-than-expected order conversion and increased costs, resulting in delays in recognising revenue. Certain overdue orders are expected to carry over into FY25, impacting the full-year results.

The Capital Equipment segment has experienced a softening in demand, particularly in the pharmaceutical sector, due to timing and budget cycles. Although long-term demand and market share remain stable, current orders do not support the strong year-end revenue typically expected in this segment. This has had a negative impact on margins, made worse

This is expected to be corrected in May/June with the elevated output and further in FY25 as the cost structure normalises.

Trajan expects record revenue in the second half of FY24 for its Components and Consumables segment, thanks to stabilising demand. Microsampling demand is also expected to grow by about 30% compared to H1 FY24. Trajan has been ramping up global production to meet this growing demand, with output increasing by around 10% in recent months, but it has not yet reached the levels required to clear the growing order backlog.

Despite this growth, the projected revenue for the microsampling segment in H2 is expected to fall between $96 million and $98 million, below earlier forecasts. The microsampling-related component of Disruptive technologies is expected to break even in FY25. The cost reduction initiatives have already been actioned to achieve this objective, with the benefits to be realised from July 2024.

Trajan is also actively working with property agents in the US and Europe to pursue the divestment, and in some cases lease-back, of property assets acquired as part of more recent acquisitions. The objective is to unlock approximately $10 million within the next 12 months to be applied to debt reduction.

Trajan has been notified that US and Chinese patents for the “Hummingbird” miniature instrument system for real-time outcome measurement will be granted. The first unit of the latest version is now in assembly. 

Recent feedback from some 25 Pharmaceutical companies has reinforced the merits of the concept and direction. In Australia, Hummingbird’s utility in field deployment for PFAS (a group of chemicals used in medical devices and fire-fighting equipment) measurement has been demonstrated. 

Trajan continues to explore different business models and potential funding arrangements to accelerate commercialisation.

 

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  •  
  •  
  •  
  •  
  • asx trj
  • microsampling
  • PFAS
  • The Capital Equipment
  • Trajan
  • Trajan Group
  • News

Leave a Comment

You must be logged in to post a comment.

1 Comment

  • Shraddha13
    April 18, 2025, 7:02 pm

    Thank you for sharing! To explore further
    https://www.360iresearch.com/library/intelligence/life-science-product-design-development-service

    Reply
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.